Cyteir Therapeutics, Inc.
Cyteir Therapeutics, Inc. (CYT): 2 pipeline candidates · ~85 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
85.4 months
D/E 0.05 · 0% dilution
Lead: Phase 2
2 candidates
N/A
N/A
A transparent, data-derived signal for Cyteir Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$129.2M
Quarterly Burn
$4.6M
Runway
85.4 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in Cyteir Therapeutics, Inc.'s pipeline?
Cyteir Therapeutics, Inc. (CYT) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Cyteir Therapeutics, Inc.'s lead drug candidate?
Cyteir Therapeutics, Inc.'s most advanced tracked candidate is cyt-0851 (Phase 2) for Relapsed and/or refractory lymphoma and/or solid tumors (including DLBCL, FL, MM, pancreatic cancer, ovarian cancer, and soft tissue sarcoma).
What is Cyteir Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Cyteir Therapeutics, Inc. has approximately 85.4 months of cash runway.
Who is the CEO of Cyteir Therapeutics, Inc.?
Directors Markus Renschler, M.D. is the chief executive officer of Cyteir Therapeutics, Inc. (CYT).
Get the full picture on Cyteir Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.